Reference intervals of HE4 and ROMA value according to age groups | Download Table
Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics
SciELO - Brasil - A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses A comparison of CA125, HE4, risk ovarian
Human Epididymis Protein 4 - an overview | ScienceDirect Topics
SciELO - Brasil - A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses A comparison of CA125, HE4, risk ovarian
Ovarian Cancer | AACC.org
Diagnostic Values of HE4, CA125, RMI and ROMA using Standard and... | Download Table
ROMA (Risk of Ovarian Malignancy Algorithm)
Specific forest map for diagnosis of ovarian cancer with the ROMA index... | Download Scientific Diagram
HE4 can Help Discriminate Women with Malignant Ovarian Tumors only if CA125 Levels are Elevated - Denise da Rocha Pitta, Luis Otávio Sarian, Elisabete Aparecida Campos, Liliana Lucci De Angelo Andrade, Luis
Diagnostics | Free Full-Text | Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors
CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages
Frontiers | Copenhagen index (CPH-I) is more favorable than CA125, HE4, and risk of ovarian malignancy algorithm (ROMA): Nomogram prediction models with clinical-ultrasonographic feature for diagnosing ovarian neoplasms
The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer
Serum CA125, HE4 and ROMA levels according to histology, FIGO stage and... | Download Table
![PDF] A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ee64ab230d3264a10ced4c6827d39d8b87b0b704/3-Table1-1.png "PDF] A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses | Semantic Scholar")
PDF] A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses | Semantic Scholar
Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer. - Abstract - Europe PMC
Diagnostics | Free Full-Text | The Comparison of Three Predictive Indexes to Discriminate Malignant Ovarian Tumors from Benign Ovarian Endometrioma: The Characteristics and Efficacy
Clinical value of ROMA index in diagnosis of ovarian cancer: meta-analysis. - Document - Gale Academic OneFile
Analysis of falsely elevated risk of ovarian malignancy algorithm in women with ovarian endometrioma
Correlations between IOTA index, CA125, HE4, ROMA index | Download Scientific Diagram
Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics
RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: A prospective population‐based study - Liest - 2019 - Acta Obstetricia et Gynecologica Scandinavica - Wiley Online Library
Clinical value of ROMA index in diagnosis of ovarian cancer: meta-analysis. - Document - Gale Academic OneFile
differences between HE4, CA125, and ROMA values and sensitivity, PPV,... | Download Scientific Diagram
JGO :: Journal of Gynecologic Oncology
HE4 can Help Discriminate Women with Malignant Ovarian Tumors only if CA125 Levels are Elevated - Denise da Rocha Pitta, Luis Otávio Sarian, Elisabete Aparecida Campos, Liliana Lucci De Angelo Andrade, Luis
Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?
Comparison of Risk of Ovarian Malignancy Algorithm and cancer antigen 125 to discriminate between benign ovarian tumor and early‑stage ovarian cancer according to imaging tumor subtypes
